Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Nichols

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
Journal of the Pediatric Infectious Diseases Society|September 7, 2022
Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway InfectionsJonathan D Cogen, David P Nichols, Christopher H Goss, et al.
Annals of Clinical and Laboratory Science|September 1, 2019
Protein Abundance Determination: An Optimized Western Blot WorkflowScott W Lallier, Cynthia L Hill, David P Nichols, et al.
Plos One|October 29, 2015
Therapeutic Effects of α1-Antitrypsin on Psedumonas aeruginosa Infection in ENaC Transgenic MiceDavid P Nichols, Di Jiang, Carrie Happoldt, et al.
Journal of Inflammation Research|November 19, 2011
Potential of anti-inflammatory treatment for cystic fibrosis lung diseaseJennifer L Taylor-Cousar, Kelsey A Von Kessel, Robert Young, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|August 25, 2009
The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung diseaseDavid P Nichols, Assem G Ziady, Samuel L Shank, et al.
The Journal of Biological Chemistry|May 1, 2013
Selective metabolism of hypothiocyanous acid by mammalian thioredoxin reductase promotes lung innate immunity and antioxidant defenseJoshua D Chandler, David P Nichols, Jerry A Nick, et al.
Arthritis and Rheumatism|November 1, 2006
Patients with juvenile psoriatic arthritis comprise two distinct populationsMatthew L Stoll, David Zurakowski, Lise E Nigrovic, et al.
Annals of the American Thoracic Society|February 24, 2018
Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory PathogensJonathan D Cogen, Frankline Onchiri, Julia Emerson, et al.
Plos One|November 19, 2011
SERCA2 regulates non-CF and CF airway epithelial cell response to ozoneShama Ahmad, David P Nichols, Matthew Strand, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 27, 2023
Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbationsAnna V Faino, Lucas R Hoffman, Ronald L Gibson, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Journal of the Pediatric Infectious Diseases Society|September 7, 2022
Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway InfectionsJonathan D Cogen, David P Nichols, Christopher H Goss, et al.
Annals of Clinical and Laboratory Science|September 1, 2019
Protein Abundance Determination: An Optimized Western Blot WorkflowScott W Lallier, Cynthia L Hill, David P Nichols, et al.
Plos One|October 29, 2015
Therapeutic Effects of α1-Antitrypsin on Psedumonas aeruginosa Infection in ENaC Transgenic MiceDavid P Nichols, Di Jiang, Carrie Happoldt, et al.
Journal of Inflammation Research|November 19, 2011
Potential of anti-inflammatory treatment for cystic fibrosis lung diseaseJennifer L Taylor-Cousar, Kelsey A Von Kessel, Robert Young, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|August 25, 2009
The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung diseaseDavid P Nichols, Assem G Ziady, Samuel L Shank, et al.
The Journal of Biological Chemistry|May 1, 2013
Selective metabolism of hypothiocyanous acid by mammalian thioredoxin reductase promotes lung innate immunity and antioxidant defenseJoshua D Chandler, David P Nichols, Jerry A Nick, et al.
Arthritis and Rheumatism|November 1, 2006
Patients with juvenile psoriatic arthritis comprise two distinct populationsMatthew L Stoll, David Zurakowski, Lise E Nigrovic, et al.
Annals of the American Thoracic Society|February 24, 2018
Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory PathogensJonathan D Cogen, Frankline Onchiri, Julia Emerson, et al.
Plos One|November 19, 2011
SERCA2 regulates non-CF and CF airway epithelial cell response to ozoneShama Ahmad, David P Nichols, Matthew Strand, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 27, 2023
Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbationsAnna V Faino, Lucas R Hoffman, Ronald L Gibson, et al.
Pageof 7